Pedro Machado to Male
This is a "connection" page, showing publications Pedro Machado has written about Male.
Connection Strength
0.042
-
Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open. 2021 02; 7(1).
Score: 0.013
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.003
-
Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021 06; 41(6):1021-1036.
Score: 0.003
-
Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barré syndrome. Brain. 2021 03 03; 144(2):682-693.
Score: 0.003
-
Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2021 03; 73(3):374-380.
Score: 0.003
-
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021 07; 80(7):930-942.
Score: 0.003
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.003
-
Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. Ann Rheum Dis. 2020 10; 79(10):1386-1388.
Score: 0.003
-
MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. Ann Rheum Dis. 2019 11; 78(11):1550-1558.
Score: 0.003
-
Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis. 2018 05; 77(5):699-705.
Score: 0.003
-
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches. Nat Commun. 2017 11 30; 8(1):1859.
Score: 0.003